Last updated: July 28, 2026
Lanoxin Pediatric (digoxin) clinical trials update, market analysis, and launch projections
Executive summary: Lanoxin Pediatric is a digoxin oral solution formulation marketed for pediatric use. Public sources do not provide a current, trackable “clinical trials update” stream specific to the pediatric product in a way that supports a complete, date-stamped review tied to the active ingredient’s modern development pipeline. Commercial projection also cannot be quantified to a decision-grade level without product-level unit and pricing inputs, and those are not available in the cited record below. What can be stated from public regulatory and patent reporting is that digoxin remains an established, off-patent small molecule in major markets, and pediatric-specific IP is typically formulation/administration related rather than a pathway-blocking new chemical entity.
What clinical trials exist for Lanoxin Pediatric (digoxin) oral solution in pediatrics?
Featured snippet answer: No pediatric digoxin trial dataset tied specifically to “Lanoxin Pediatric” as a unique branded product is available in the cited sources below. Clinical development for digoxin is largely historical and/or uses digoxin generically rather than branding-specific protocols.
Which study types typically cover digoxin in children
Digoxin pediatric evidence in public registries historically centers on:
- pharmacokinetics (PK) and dosing in infants and children,
- safety and tolerability in pediatric heart failure and arrhythmia settings,
- therapeutic drug monitoring (TDM) and exposure-response in relation to target serum concentrations.
What to expect for a branded pediatric formulation
For long-established oral solutions, trial activity tends to fall into:
- bridging studies to confirm bioavailability or comparable PK after formulation changes,
- stability and in-use shelf-life comparisons,
- label expansion studies tied to dosing regimens rather than new mechanisms.
Is Lanoxin Pediatric supported by FDA approval, and what is the current regulatory status?
Featured snippet answer: Digoxin is FDA-approved for pediatric indications under established labeling. Public records for “Lanoxin Pediatric” specifically are not included in the cited dataset below.
FDA product framework for older small molecules
For legacy digoxin products, FDA status is usually maintained through:
- NDA holder labeling,
- postmarketing requirements (PMRs) or commitments tied to safety updates,
- Orange Book listings that reflect patents covering formulation, method-of-use, or packaging rather than new active ingredient IP.
Orange Book status: what matters for “pediatric”
If pediatric exclusivity existed for Lanoxin Pediatric, it would show up as:
- formulation patents (composition of matter or specific solution characteristics),
- method-of-use patents (pediatric dosing regimens or therapeutic targets),
- exclusivity blocks tied to an NDA supplement.
No Orange Book listing record is included in the cited sources below, so no definitive Orange Book status table can be produced here.
What patents protect Lanoxin Pediatric digoxin solution and how long do they last?
Featured snippet answer: Digoxin’s active ingredient is long off new-compound exclusivity. Any remaining “Lanoxin Pediatric” protection, if present, would most likely relate to pediatric formulation specifics or labeling-driven method-of-use claims. A complete patent estate map cannot be populated from the cited record below.
Patent estate structures that can remain for older drugs
Even when the API is old, protection can persist via:
- specific formulation composition (excipients, concentration, pH, stability system),
- container closure systems and delivery constraints,
- pediatric dosing/indication claims if they were patented later.
Licensing and generic-entry risk drivers
For older small molecules with formulation patents, generic risk typically depends on:
- whether the generic can use FDA-approved bioequivalence without infringing formulation claims,
- design-around freedom for excipients and manufacturing process steps.
When does digoxin lose exclusivity and what generic entry risks exist for pediatric oral solution?
Featured snippet answer: For digoxin, the practical exclusivity barrier for new entry is usually patent-by-patent, not a single fixed exclusivity date. A generic risk call requires a live Orange Book-to-patent mapping that is not present in the cited sources below.
Practical generic entry scenarios for oral solutions
Generic entry often hinges on:
- establishing bioequivalence for an oral solution,
- matching concentration and dosing-measure delivery,
- meeting stability specs for shelf life and in-use periods.
How big is the market for Lanoxin Pediatric (digoxin pediatric oral solution), and where does it sit vs adult digoxin?
Featured snippet answer: A full product-level market size for Lanoxin Pediatric cannot be quantified from the cited record below. Digoxin demand is driven by:
- congenital and pediatric arrhythmia management workflows,
- hospital formulary inclusion and substitution behavior,
- competition from generic digoxin oral solutions and tablets.
Demand drivers for pediatric digoxin
- use cases that still require TDM and concentration targeting,
- institutional protocols that prefer established dosing regimens,
- limited pediatric oral solution alternatives in certain dosing ranges.
Substitution behavior
In pediatric markets, substitution is constrained by:
- prescriber familiarity with a specific concentration,
- dosing-device compatibility,
- stability and bioavailability equivalence acceptance.
What pricing and reimbursement dynamics affect Lanoxin Pediatric sales projections?
Featured snippet answer: Sales projections for an off-patent legacy digoxin product are typically dominated by:
- generic price erosion,
- payer preference tiers for oral solution dosage forms,
- hospital procurement contracting cycles.
Key projection mechanics (inputs missing in cited sources)
A decision-grade forecast needs:
- WAC to net price conversion for pediatric accounts,
- unit volumes by strength and bottle size,
- mix shift between pediatric solution and adult solid oral forms.
Those inputs are not provided in the cited record below, so quantified projections cannot be produced.
How do you project Lanoxin Pediatric revenue when the drug is mature and off-patent?
Featured snippet answer: Mature product forecasts use a decline and mix model anchored to generic erosion and procurement dynamics. A full numeric projection is not deliverable without product-unit and net-price data.
Model structure commonly used
- Base year unit volume by strength and pack size.
- Patient utilization or diagnosis prevalence proxy.
- Market share drift to generics and store-brand equivalents.
- Contracted price erosion and rebates.
- Regulatory or supply events affecting availability.
What clinical and safety evidence matters most for digoxin pediatric use?
Featured snippet answer: For digoxin pediatric dosing, the dominant safety and efficacy determinants are:
- serum digoxin concentration control,
- renal function and drug interaction management,
- avoidance of toxicity in dosing errors.
Operational risk factors
- dosing-measure inaccuracies for oral solutions,
- concurrent medications affecting digoxin levels (classically interacting drugs),
- renal impairment requiring tighter monitoring.
Key Takeaways
- “Lanoxin Pediatric” is a digoxin pediatric oral solution; the product is mature and tied to an old active ingredient where ingredient exclusivity is not a meaningful near-term barrier.
- A complete, date-stamped “clinical trials update” specific to Lanoxin Pediatric cannot be generated from the cited record below.
- A quantified market analysis and revenue projection for Lanoxin Pediatric cannot be produced in a decision-grade manner without product-level unit and net-price inputs, which are not in the cited record below.
- The remaining competitive and legal landscape for such products typically turns on formulation- and labeling-related patents, not on new chemical entity exclusivity.
FAQs
- What are the most common pediatric digoxin dosing and monitoring endpoints used in clinical studies?
- Do digoxin pediatric oral solutions face dosing-device or concentration matching requirements for generic substitution?
- How do renal function changes alter pediatric digoxin exposure and toxicity risk?
- What patent claim types most often survive for legacy oral solution drugs after active ingredient exclusivity ends?
- What procurement and payer levers most strongly influence sales of off-patent pediatric oral solutions?
References (APA)
- FDA. (n.d.). Drug development and approval resources (general). U.S. Food and Drug Administration. https://www.fda.gov/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- ClinicalTrials.gov. (n.d.). Lanoxin Pediatric and digoxin pediatric search results (database). U.S. National Library of Medicine. https://clinicaltrials.gov/
